Xenetic Biosciences (NASDAQ: XBIO) and privately held Santersus AG have entered into a definitive share exchange agreement that would combine the two biotechnology companies and create a Nasdaq-listed company focused on therapies targeting neutrophil extracellular traps, or NETs.
Under the agreement, Xenetic will acquire all outstanding shares of Santersus in exchange for newly issued Xenetic common stock. Following closing, Santersus shareholders are expected to own approximately 85% of the combined company, while existing Xenetic shareholders are expected to own approximately 15%. The combined company is expected to be renamed Santersus Bio, Inc. and trade on Nasdaq under the ticker SNTS.
Although Xenetic is technically the acquiring entity, the ownership and governance structure make the transaction more akin to a strategic combination than a conventional acquisition. Santersus shareholders will hold the large majority of the post-transaction equity, Santersus management is expected to lead the combined company, and the new board is expected to include six Santersus nominees and two Xenetic nominees.
Building a Broader NET-Targeting Platform
The strategic rationale centers on combining complementary approaches to targeting NETs.
NETs are web-like structures released by neutrophils as part of the immune response. While they can help trap pathogens, excessive or persistent NET formation has also been implicated in inflammation, thrombosis, tissue injury and disease progression across a range of conditions.
Santersus is developing NucleoCapture, a therapeutic blood-filtration platform designed to remove circulating NETs and related pathogenic components directly from the bloodstream. The company has been pursuing applications in conditions including sepsis, systemic lupus erythematosus and liver transplantation.
Xenetic brings a different approach through its DNase platform, which is designed to enzymatically degrade NETs. Xenetic has been developing this approach primarily in oncology, including as a potential way to improve the effectiveness of cancer therapies such as CAR-T by reducing the protective effects NETs may provide within the tumor microenvironment.
The combined company would therefore have both extracorporeal and biologic approaches to the same broad target, creating a portfolio that spans inflammatory disease, transplantation and oncology.
Santersus Brings the Lead Clinical-Stage Asset
Santersus’ NucleoCapture platform is expected to become the principal clinical development focus of the combined company. The technology is designed to filter NETs and other disease-associated extracellular material from circulating blood without broadly suppressing the immune system. Santersus has positioned the platform for acute and immune-mediated conditions where excessive NET formation may contribute to disease severity.
The company’s development programs include sepsis, lupus and liver transplantation, areas where treatment options can be limited and where severe inflammatory responses may cause substantial organ damage. For Xenetic, the transaction significantly broadens its development pipeline while moving the combined organization closer to clinically advanced opportunities than Xenetic would have on its own.
Governance Reflects the Economic Structure
The post-transaction governance reinforces the fact that this is not a typical buyer-target acquisition. Santersus’ leadership is expected to run the combined company, while Xenetic will contribute its Nasdaq listing, existing programs and corporate infrastructure. The board composition is also expected to tilt heavily toward Santersus, consistent with the roughly 85/15 ownership split.
That makes the transaction structurally similar to other biotech combinations in which a private company gains access to the public markets through a merger with an existing listed entity. For investors, the key point is that the future investment thesis will be driven primarily by Santersus’ clinical programs and the broader NET-targeting strategy, rather than by Xenetic’s historical business alone.
Why NET Biology Is Drawing Interest
The scientific interest in NETs has grown as researchers have linked excessive NET formation to a wide range of inflammatory, thrombotic and immune-mediated diseases. In sepsis, NETs may contribute to microvascular obstruction, inflammation and organ damage. In autoimmune disease, persistent NET formation has been associated with immune dysregulation. In transplantation, the same inflammatory mechanisms may contribute to ischemia-reperfusion injury and graft dysfunction.
That broad biological relevance creates opportunities, but it also raises an important development challenge: showing that targeting NETs can translate into meaningful clinical outcomes across specific indications. The combined Santersus/Xenetic company will need to demonstrate not only that NET burden can be reduced, but that doing so improves patient outcomes in well-defined patient populations.
A Broader Biotech Theme: Controlling Harmful Immune Responses
The transaction also fits into a wider biotechnology trend involving therapies designed to control damaging immune activity without broadly shutting down the immune system.
One related company followed by Noble Capital Markets is Eledon Pharmaceuticals (NASDAQ: ELDN). Eledon is developing tegoprubart, an anti-CD40L antibody designed to prevent immune rejection in organ and islet-cell transplantation while avoiding some of the limitations associated with conventional immunosuppressive drugs. Noble research has highlighted Eledon’s kidney-transplant and islet-transplant programs as the company advances tegoprubart through clinical development.
The mechanisms are different, but the strategic overlap is clear: both Santersus and Eledon are pursuing more targeted ways to address harmful immune activity in settings where excessive inflammation or immune rejection can drive poor outcomes.
Cadrenal Adds a Critical-Care Parallel
Another Noble-covered company with a related critical-care angle is Cadrenal Therapeutics (NASDAQ: CVKD). Cadrenal is developing therapies for serious thrombotic and cardiovascular conditions, including tecarfarin and CAD-1005. Its pipeline includes programs in heparin-induced thrombocytopenia and other acute-care settings where thrombosis and coagulation abnormalities can create significant clinical risk.
Again, the biology is different, but Cadrenal provides another example of a small-cap biotechnology company targeting severe, high-risk conditions where existing therapies may be inadequate and where improved control of inflammation, coagulation or immune dysfunction could have meaningful clinical value.
A Public-Market Reset for Xenetic
For Xenetic shareholders, the transaction represents a major reset of the company’s strategic direction. If completed, the combined company will be much more heavily defined by Santersus, both economically and operationally. Existing Xenetic shareholders will retain a minority position in a broader NET-targeting platform that includes multiple clinical indications and a new management team.
For Santersus, the agreement provides a path to the U.S. public markets and access to a Nasdaq-listed platform without pursuing a traditional initial public offering. The result is a combination designed to create a more diversified biotechnology company around a relatively focused scientific thesis: that excessive NET formation plays a meaningful role across inflammatory, transplant and oncology indications, and that directly targeting those NETs could create new therapeutic opportunities.
If the transaction closes as planned, investors will be evaluating the new Santersus Bio less as a continuation of Xenetic and more as a newly assembled NET therapeutics company with a substantially different pipeline, ownership structure and clinical focus.
